Evaluation of 10-minute post-injection11C-PiB PET and its correlation with18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer’s disease

2Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Objective: Positron emission tomography (PET) allows in vivo evaluation of molecular targets in neurodegenerative diseases, such as Alzheimer’s disease. Mild cognitive impairment is an intermediate stage between normal cognition and Alzheimer-type dementia. In vivo fibrillar amyloid-beta can be detected in PET using [11C]-labeled Pittsburgh compound B (11C-PiB). In contrast, [18F] fluoro-2-deoxy-d-glucose (18F-FDG) is a neurodegeneration biomarker used to evaluate cerebral glucose metabolism, indicating neuronal injury and synaptic dysfunction. In addition, early cerebral uptake of amyloid-PET tracers can determine regional cerebral blood flow. The present study compared early-phase11C-PiB and18F-FDG in older adults without cognitive impairment, amnestic mild cognitive impairment, and clinical diagnosis of probable Alzheimer’s disease. Methods: We selected 90 older adults, clinically classified as healthy controls, with amnestic mild cognitive impairment, or with probable Alzheimer’s disease, who underwent an18F-FDG PET, early-phase11C-PiB PET and magnetic resonance imaging. All participants were also classified as amyloid-positive or-negative in late-phase11C-PiB. The data were analyzed using statistical parametric mapping. Results: We found that the probable Alzheimer’s disease and amnestic mild cognitive impairment group had lower early-phase11C-PiB uptake in limbic structures than18F-FDG uptake. The images showed significant interactions between amyloid-beta status (negative or positive). However, early-phase11C-PiB appears to provide different information from18F-FDG about neurodegeneration. Conclusions: Our study suggests that early-phase11C-PiB uptake correlates with18F-FDG, irrespective of the particular amyloid-beta status. In addition, we observed distinct regional distribution patterns between both biomarkers, reinforcing the need for more robust studies to investigate the real clinical value of early-phase amyloid-PET imaging.

Cite

CITATION STYLE

APA

Carneiro, C. de G., Faria, D. de P., Coutinho, A. M., Ono, C. R., Duran, F. L. de S., da Costa, N. A., … Buchpiguel, C. A. (2022). Evaluation of 10-minute post-injection11C-PiB PET and its correlation with18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer’s disease. Brazilian Journal of Psychiatry, 44(5), 495–506. https://doi.org/10.47626/1516-4446-2021-2374

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free